CN103298807A - 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物 - Google Patents

作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物 Download PDF

Info

Publication number
CN103298807A
CN103298807A CN2011800639683A CN201180063968A CN103298807A CN 103298807 A CN103298807 A CN 103298807A CN 2011800639683 A CN2011800639683 A CN 2011800639683A CN 201180063968 A CN201180063968 A CN 201180063968A CN 103298807 A CN103298807 A CN 103298807A
Authority
CN
China
Prior art keywords
phenyl
trifluoromethyl
oxadiazol
chroman
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800639683A
Other languages
English (en)
Chinese (zh)
Inventor
R.J.彻尼
王中玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN103298807A publication Critical patent/CN103298807A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2011800639683A 2010-11-03 2011-11-02 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物 Pending CN103298807A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40968210P 2010-11-03 2010-11-03
US61/409,682 2010-11-03
PCT/US2011/058891 WO2012061459A1 (en) 2010-11-03 2011-11-02 Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases

Publications (1)

Publication Number Publication Date
CN103298807A true CN103298807A (zh) 2013-09-11

Family

ID=44983720

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800639683A Pending CN103298807A (zh) 2010-11-03 2011-11-02 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物

Country Status (6)

Country Link
US (1) US8629282B2 (https=)
EP (1) EP2635573B1 (https=)
JP (1) JP2013544811A (https=)
CN (1) CN103298807A (https=)
ES (1) ES2525298T3 (https=)
WO (1) WO2012061459A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014862A1 (zh) * 2016-07-22 2018-01-25 南京明德新药研发股份有限公司 S1p1激动剂及其应用
WO2019141245A1 (zh) * 2018-01-18 2019-07-25 南京明德新药研发股份有限公司 一种三并环化合物的晶型、盐型及其制备方法
CN115038437A (zh) * 2019-11-20 2022-09-09 艾尼纳制药公司 治疗与s1p1受体相关的病症的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換３−フェニル−１，２，４−オキサジアゾール化合物
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
EP4061352A4 (en) * 2019-11-19 2024-02-28 Trevena, Inc. COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1788008A (zh) * 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
WO2009080728A1 (en) * 2007-12-21 2009-07-02 Glaxo Group Limited Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
WO2010069949A1 (en) * 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
WO2010072352A1 (en) * 2008-12-26 2010-07-01 Almirall S.A. 1, 2, 4 -oxadiazole derivatives and their therapeutic use
WO2010081692A1 (en) * 2009-01-19 2010-07-22 Almirall, S.A. Oxadiazole derivatives as slpl receptor agonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
US7309721B2 (en) 2002-03-01 2007-12-18 Merck + Co., Inc. Aminoalkylphosphonates and related compounds as Edg receptor agonists
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
BRPI0609668A2 (pt) 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2007024922A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
JP2009530389A (ja) 2006-03-21 2009-08-27 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物及びその使用
MX2008012738A (es) 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
ES2400163T3 (es) 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
ES2622423T3 (es) 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
RU2010121969A (ru) 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
US20090298894A1 (en) * 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
EP2389377B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
ES2405054T3 (es) * 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
JP5728487B2 (ja) 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式ヘテロ環化合物
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換３−フェニル−１，２，４−オキサジアゾール化合物
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1788008A (zh) * 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
WO2009080728A1 (en) * 2007-12-21 2009-07-02 Glaxo Group Limited Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
WO2010069949A1 (en) * 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
WO2010072352A1 (en) * 2008-12-26 2010-07-01 Almirall S.A. 1, 2, 4 -oxadiazole derivatives and their therapeutic use
WO2010081692A1 (en) * 2009-01-19 2010-07-22 Almirall, S.A. Oxadiazole derivatives as slpl receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘魏，等: "免疫抑制剂的研究新进展", 《药学进展》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014862A1 (zh) * 2016-07-22 2018-01-25 南京明德新药研发股份有限公司 S1p1激动剂及其应用
CN109661391A (zh) * 2016-07-22 2019-04-19 石家庄智康弘仁新药开发有限公司 S1p1激动剂及其应用
US11192886B2 (en) 2016-07-22 2021-12-07 Medshine Discovery Inc. S1P1 agonist and application thereof
CN109661391B (zh) * 2016-07-22 2022-04-19 南京明德新药研发有限公司 S1p1激动剂及其应用
WO2019141245A1 (zh) * 2018-01-18 2019-07-25 南京明德新药研发股份有限公司 一种三并环化合物的晶型、盐型及其制备方法
CN111683946A (zh) * 2018-01-18 2020-09-18 石家庄智康弘仁新药开发有限公司 一种三并环化合物的晶型、盐型及其制备方法
US11465995B2 (en) 2018-01-18 2022-10-11 Medshine Discovery Inc. Crystal and salt forms of tricyclic compound and preparation process thereof
CN115038437A (zh) * 2019-11-20 2022-09-09 艾尼纳制药公司 治疗与s1p1受体相关的病症的方法
TWI895298B (zh) * 2019-11-20 2025-09-01 美商艾尼納製藥公司 受體相關之病況的方法

Also Published As

Publication number Publication date
US8629282B2 (en) 2014-01-14
US20130237566A1 (en) 2013-09-12
JP2013544811A (ja) 2013-12-19
EP2635573A1 (en) 2013-09-11
WO2012061459A1 (en) 2012-05-10
ES2525298T3 (es) 2014-12-19
EP2635573B1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
CN103298807A (zh) 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
EP2592071B1 (en) Tricyclic heterocyclic compounds
EP2382212B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
US8389509B2 (en) Substituted pyrazole compounds
US8404672B2 (en) Substituted heterocyclic compounds
CN103237795B (zh) 经取代的噁二唑化合物及其作为s1p1激动剂的用途
ES2533095T3 (es) Agonistas de receptores de esfingosina-1-fosfato
ES2548683T3 (es) Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
JP7029445B2 (ja) 置換された三環式ヘテロ環化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20170111

AD01 Patent right deemed abandoned